15 October 2015 - Bristol-Myers Squibb today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir dihydrochloride) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4.

For more details, go to: http://news.bms.com/press-release/nice-recommends-daklinza-daclatasvir-treatment-certain-patients-chronic-hepatitis-c-ge